Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- IMNM
- Price
- 25.82
- Stock movement up
- +0.95 (3.82%)
- Company name
- Immunome Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 2.85B
- Ent value
- 2.61B
- Price/Sales
- 294.33
- Price/Book
- 10.79
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 15.99%
- 1 year return (CAGR)
- 153.88%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
IMNM does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 294.33 |
| Price to Book | 10.79 |
| EV to Sales | 269.83 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 110.34M |
| EPS (TTM) | -2.53 |
| FCF per share (TTM) | -2.18 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 9.68M |
| Gross profit (TTM) | -40.23M |
| Operating income (TTM) | -234.22M |
| Net income (TTM) | -222.74M |
| EPS (TTM) | -2.53 |
| EPS (1y forward) | -2.56 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -415.68% |
| Operating margin (TTM) | -2419.90% |
| Profit margin (TTM) | -2301.30% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 272.64M |
| Net receivables | 0.00 |
| Total current assets | 279.92M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 14.69M |
| Total assets | 299.38M |
| Accounts payable | 6.15M |
| Short/Current long term debt | 4.01M |
| Total current liabilities | 31.45M |
| Total liabilities | 35.46M |
| Shareholder's equity | 263.92M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -185.03M |
| Capital expenditures (TTM) | 7.06M |
| Free cash flow (TTM) | -192.09M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -84.40% |
| Return on Assets | -74.40% |
| Return on Invested Capital | -84.40% |
| Cash Return on Invested Capital | -72.78% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 24.84 |
| Daily high | 25.85 |
| Daily low | 24.50 |
| Daily Volume | 2.86M |
| All-time high | 43.24 |
| 1y analyst estimate | 34.25 |
| Beta | 2.18 |
| EPS (TTM) | -2.53 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 19 Mar 2026 |
Downside potential
Loading...
Downside potential data
| IMNM | S&P500 | |
| Current price drop from All-time high | -40.29% | -0.89% |
| Highest price drop | -87.14% | -19.00% |
| Date of highest drop | 8 Apr 2025 | 8 Apr 2025 |
| Avg drop from high | -72.39% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 322 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
2.85B
Marketcap category
Mid-cap
Description
Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. Its preclinical assets include IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, including IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Employees
168
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page